Christian Guido Ruf1,2, Nojan Sanatgar3, Hendrik Isbarn4, Birgit Ruf5, Jörg Simon6, Christian Daniel Fankhauser7, Klaus-Peter Dieckmann8. 1. Bundeswehrkrankenhaus Hamburg, Hamburg, Germany. Dr.ChristianRuf@gmx.de. 2. Abteilung für Urologie, Bundeswehrkrankenhaus Ulm, Oberer Eselsberg 40, 89081, Ulm, Germany. Dr.ChristianRuf@gmx.de. 3. Bundeswehrkrankenhaus Hamburg, Hamburg, Germany. 4. Martini Klinik Hamburg, Hamburg, Germany. 5. Asklepios Klinik Harburg, Hamburg, Germany. 6. Ortenau-Klinikum Offenburg, Offenburg, Germany. 7. Universität Zürich, Zürich, Switzerland. 8. Asklepios Klinik Altona, Hamburg, Germany.
Abstract
PURPOSE: Leydig-cell tumours (LCT) of the testis are poorly understood clinically. The aim of this report is to analyse the clinical characteristics of LCT in a large patient sample and to compare these findings with corresponding data of germ-cell tumours (GCT). METHODS: In a sample of 208 patients treated during 1995-2017 in 33 institutions, the following characteristics were registered: age, presenting symptoms, primary tumour size, testis-sparing surgery (TSS) or orchiectomy, malignancy, laterality, medical history, and outcome. Data analysis included descriptive statistical methods and logistic regression analysis. RESULTS: The ratio LCT:GCT is 1:23 (4.4%). The findings are as follows: median age 41 years, undescended testis 8%, bilateral LCTs 3%, malignant LCT 2.5%, contralateral GCT 2.5%, incidental detection 28%, scrotal symptoms 43%, infertility 18%, elevated estradiol levels 29%. TSS was performed in 56% with no local relapse. Of the patients with malignant LCT, one was cured through surgery. CONCLUSION: LCT is rare, with a relative frequency (relative to GCT) of 1:23. Malignancy is found in 2.5%. LCT and GCT share a number of clinical features, e.g. bilaterality, history of undescended testis, and presenting age. TSS is safe in benign LCT. Surgery is the treatment of choice in malignant LCT.
PURPOSE:Leydig-cell tumours (LCT) of the testis are poorly understood clinically. The aim of this report is to analyse the clinical characteristics of LCT in a large patient sample and to compare these findings with corresponding data of germ-cell tumours (GCT). METHODS: In a sample of 208 patients treated during 1995-2017 in 33 institutions, the following characteristics were registered: age, presenting symptoms, primary tumour size, testis-sparing surgery (TSS) or orchiectomy, malignancy, laterality, medical history, and outcome. Data analysis included descriptive statistical methods and logistic regression analysis. RESULTS: The ratio LCT:GCT is 1:23 (4.4%). The findings are as follows: median age 41 years, undescended testis 8%, bilateral LCTs 3%, malignant LCT 2.5%, contralateral GCT 2.5%, incidental detection 28%, scrotal symptoms 43%, infertility 18%, elevated estradiol levels 29%. TSS was performed in 56% with no local relapse. Of the patients with malignant LCT, one was cured through surgery. CONCLUSION:LCT is rare, with a relative frequency (relative to GCT) of 1:23. Malignancy is found in 2.5%. LCT and GCT share a number of clinical features, e.g. bilaterality, history of undescended testis, and presenting age. TSS is safe in benign LCT. Surgery is the treatment of choice in malignant LCT.
Authors: Yin Huang; Bo Chen; Dehong Cao; Zeyu Chen; Jin Li; Jianbing Guo; Qiang Dong; Qiang Wei; Liangren Liu Journal: Front Med (Lausanne) Date: 2022-05-31
Authors: Christian Daniel Fankhauser; Josias Bastian Grogg; Christian Rothermundt; Noel William Clarke Journal: J Cancer Res Clin Oncol Date: 2022-01-20 Impact factor: 4.553